<DOC>
	<DOCNO>NCT00361296</DOCNO>
	<brief_summary>RATIONALE : Vaccines make cancer cell may help body build effective immune response kill abnormal cell . PURPOSE : This clinical trial study well vaccine therapy work treat patient myelodysplastic syndrome ( MDS ) .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety GM-K562 cell vaccine patient myelodysplastic syndrome . - Determine hematologic cytogenetic response patient treat vaccine . Secondary - Determine vaccination GM-K562 cell vaccine induce immune response common myeloid antigen ( e.g. , Wilms ' tumor-1 [ WT-1 ] , survivin , proteinase-3 ) , define 30 % increase baseline specific cytotoxic T-cells measure Elispot assay , patient myelodysplastic syndrome . - Determine immune response correlate clinical response ( e.g. , hematologic response , resolution cytogenetic abnormality , decrease parameter , WT-1 mRNA level ) . OUTLINE : This open-label study . Patients receive GM-K562 cell vaccine subcutaneously week 0 , 3 , 6 , 9 , 17 absence disease progression unacceptable toxicity . Blood tissue sample collect periodically correlative biomarker study . Samples analyze cytogenetic study , fluorescent situ hybridization ( FISH ) , flow cytometry . Elispot use quantify cellular cytotoxic T-cell response Wilms ' tumor-1 ( WT-1 ) , survivin , proteinase 3 . After completion study treatment , patient follow every 3 month 1 year . PROJECTED ACCRUAL : A total 15 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm myelodysplastic syndrome ( MDS ) , include follow : Refractory anemia ( RA ) RA ring sideroblast Refractory cytopenia multilineage dysplasia ( RCMD ) RCMD ring sideroblast RA excess blast 1 ( 59 % blast ) RA excess blast 2 ( 1019 % blast ) Must poorrisk MDS , define following : At least 2 lineage involve Unfavorable cytogenetics ( i.e. , abnormalities chromosome 5 7 , 11q23 , [ 6 ; 9 ] , trisomy 8 , inv3 , multiple/complex karyotype ) Transfusion requirement &gt; 2 unit pack red blood cell monthly No chronic myelomonocytic leukemia No transformation acute myeloid leukemia PATIENT CHARACTERISTICS : ECOG performance status 02 Creatinine &lt; 2.5 mg/dL Bilirubin &lt; 2.5 mg/dL ( unless due Gilbert 's syndrome ) Room air oxygen saturation â‰¥ 94 % rest Fertile patient must use effective contraception Negative pregnancy test No malignancy within past 5 year except situ cervical cancer adequately treat nonmelanoma skin cancer No active autoimmune disease history autoimmune disease require systemic immunosuppressant include , limited , follow : Autoimmune hemolytic anemia Idiopathic thrombocytopenia purpura Inflammatory bowel disease Vasculitis Thyroiditis Rheumatic illnesses No known HIV serum antibody positivity No disease require longterm corticosteroid immunosuppressant , severe chronic obstructive pulmonary disease asthma PRIOR CONCURRENT THERAPY : At least 2 week since prior systemic corticosteroid immunosuppressant ( e.g. , cyclosporine , azathioprine , tacrolimus , mycophenolate mofetil ) At least 3 week since prior growth factor At least 2 month since prior azacitidine MDS No prior bone marrow organ transplantation No concurrent cytotoxicbased therapy MDS No concurrent growth factor , include epoetin alfa , filgrastim ( GCSF ) , sargramostim ( GMCSF )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>